Bayer reported positive Phase III FIND-CKD trial results for its drug Kerendia (finerenone).
The drug significantly slowed kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD).
Kerendia met its primary endpoint as measured by the estimated glomerular filtration rate (eGFR) slope.
The treatment demonstrated a statistically significant reduction in composite kidney-cardiovascular risks versus placebo.
This study represents the fifth consecutive successful Phase III trial for the drug.
Results were presented at the 63rd European Renal Association (ERA) Congress and published in the New England Journal of Medicine.